BUSCOPAN INJECTION FOR HORSES DIN 02282089
Status: Marketed
Holder: BOEHRINGER INGELHEIM ANIMAL HEALTH CANADA INC.
Molecule: HYOSCINE BUTYLBROMIDE
Health Canada record
| Active ingredient(s) | HYOSCINE BUTYLBROMIDE 20 MG |
|---|---|
| Dosage form | Solution |
| Route | Intravenous |
| Schedule | PRESCRIPTION |
| Class | Veterinary |
| ATC | |
| Original market date | 03-Mar-2008 |
| Current status date | 12-Aug-2020 |
| Source | Health Canada DPD |
Establishment licence of the holder
Boehringer Ingelheim (Canada) Ltd Ltee — licence 100187, currently licensed, last inspection rating C (2025-03-03).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing HYOSCINE BUTYLBROMIDE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02512335 | ACCEL-HYOSCINE | ACCEL PHARMA INC | Tablet | HYOSCINE BUTYLBROMIDE 10 MG | Marketed |
| 00363812 | BUSCOPAN | SANOFI CONSUMER HEALTH INC | Tablet | HYOSCINE BUTYLBROMIDE 10 MG | Marketed |
| 00363839 | BUSCOPAN | SANOFI CONSUMER HEALTH INC | Solution | HYOSCINE BUTYLBROMIDE 20 MG | Marketed |
| 02229868 | HYOSCINE BUTYLBROMIDE INJECTION | SANDOZ CANADA INCORPORATED | Solution | HYOSCINE BUTYLBROMIDE 20 MG | Marketed |
| 02560984 | HYOSCINE BUTYLBROMIDE INJECTION | AS KALCEKS | Solution | HYOSCINE BUTYLBROMIDE 20 MG | Approved |
| 02508419 | HYOSCINE BUTYLBROMIDE INJECTION BP | OMEGA LABORATORIES LIMITED | Solution | HYOSCINE BUTYLBROMIDE 20 MG | Marketed |
| 00363820 | BUSCOPAN SUP 10MG | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | Suppository | HYOSCINE BUTYLBROMIDE 10 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 24017 | 2020-08-12 | New Drug Submission (NDS) | Administrative: Change in Product Ownership |
| 8129 | 2006-07-10 | New Drug Submission (NDS) |
International API supply for HYOSCINE BUTYLBROMIDE
7 valid EDQM Certificates of Suitability from 7 holders.
Request a quote for BUSCOPAN INJECTION FOR HORSES